Johnson & Johnson has officially opened its new Asia Pacific headquarters in Singapore. This is in a bid to tackle healthcare challenges in the region, and offer more patients, customers and consumers more accessible, affordable, locally relevant and impactful products and solutions.
Located in Singapore’s Science Park, the headquarters houses three new key facilities – a Leadership Lab, a Design Lab and a Johnson & Johnson Human Performance Institute. These facilities look to spur innovative ways of working in the region and drive deeper collaboration with partners across the entire healthcare ecosystem, including government bodies, healthcare agencies and academic institutions. The new regional headquarters also brings more than 1,400 employees from the pharmaceutical, medical devices and consumer business together.
According to the company, the Johnson & Johnson Leadership Lab marks its first international Leadership Lab, and is aimed at developing healthcare leaders in areas of innovation, research, exchange and dialogue among others. The lab will also open its doors to the wider community of healthcare leaders in Singapore and the region, driving collaborative connections with universities, research groups, governments and healthcare organizations.
The Design Lab housed in the Singapore headquarters is its first outside New York City. Fueled by local insights and research, the lab will focus primarily on creating products and solutions that will spur growth of a regional pipeline of products designed in Asia Pacific for both the region and the entire world.
In addition, its Human Performance Institute is also the company’s first facility outside the United States. With over 30 years of proprietary research and work with top performers, it aims to deliver science-based energy management training to help individuals, teams and organizations in Singapore and across the region achieve sustained high performance.
The Singapore Institute will be supported by an elite group of coaches who will be developing content customised for the Asia Pacific region with the hopes of improving the health and performance by 2020.
